References

Andersson K-E, Ekstrom B, Mattiasson A (1988) Actions of terodiline, its isomers and main metabolite on isolated detrusor muscle from rabbit and man. Acta Pharmacol Toxicol 63: 390-5.

Asscher AW (1991) Terodiline (Micturin) and adverse cardiac events. Committee on Safety of Medicines (letter).

Ben-David J, Zipes DP (1993) Torsades de pointes and proarrhythmia. Lancet 341: 1578-82.

Connolly MJ, Astridge PS, White EG, Morley CA, Campbell Cowan J (1991) Torsades de pointes ventricular tachycardia and terodiline. Lancet 338: 344-5.

Desertenne F (1966) La tachycardie ventriculaire a deux foyers opposes variable. Archives des Maladies du Coeur et des Vaisseaux 59: 263-72.

Hall GC, Chukwujindu J, Richardson J, Lis Y, Wild RN (1993) Micturin (terodiline hydrochloride), torsades de pointe and other arrhythmias—a study using the VAMP database. Pharmacoepidemiology and Drug Safety 2: 127-32.

Hallen B, Bogentoft S, Sandquist S, Stromberg S, Setterberg G, Ryd-Kjellen E (1989) Tolerability and steady state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence. Eur J Clin Pharmacol 36: 487-93.

Hartigan-Go K, Bateman N, Daly AK, Thomas SHL (1996) Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 60: 89-98.

Hussain RM, Hartigan-Go K, Thomas SHL, Ford GA (1996) Effect of oxybutinin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 41: 73-5.

Husted S, Andersson K-E, Sommer L, Ostergaard JR (1980) Anticholinergic and calcium antagonistic effects of terodiline in rabbit urinary bladder. Acta Pharmacologica et Toxicologica (Copenhagen) (Suppl 1), 46: 20-30.

Inman W, Clarke J, Wilton L, Pearce G, Veldhuis GJ (1993) PEM Report Number 2. Terodiline. Pharmacoepidemiology and Drug Safety 2: 287-319.

Langtry HD, McTavish D (1990) Terodiline: a review of its pharmacological properties and therapeutic use in the treatment of urinary incontinence. Drugs 40: 748 -61.

McCleod AA, Thorogood S, Barnett S (1991) Torsades de pointes complicating treatment with terodiline. Br Med J 302: 1469.

Shuba LM, Kasamaki Y, Jones SE, Ogura T, McCul-lough JR, McDonald TF (1999) Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline. J Pharmacol Exp Ther 290: 1417 -26.

Stewart DA, Taylor J, Ghosh S, Macphee GJA, Abdullah I, McLenachan, Stott DJ (1992) Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 42: 577-580.

Stratman HS, Kennedy HL (1987) Torsades de pointes associated with drugs and toxins: recognition and management. Am Heart J 113: 1470-82.

Thomas SHL, Higham PD, Hartigan-Go K, Kamali F, Wood P, Campbell RWF, Ford GA (1995)

Concentration dependent cardiotoxicity of terodi-line in patients treated for urinary incontinence. Br Heart J 74: 53-6.

Wild RN (1992) Micturin and torsades de pointe— experience of a post-marketing alert. Pharmacoepidemiology and Drug Safety 1: 147-150.

Yap YG, Camm J (2000) Risk of torsades de pointes with non-cardiac drugs. Br Med J 320: 1158-9.

Was this article helpful?

0 0
Drug Free Life

Drug Free Life

How To Beat Drugs And Be On Your Way To Full Recovery. In this book, you will learn all about: Background Info On Drugs, Psychological Treatments Statistics, Rehab, Hypnosis and Much MORE.

Get My Free Ebook


Post a comment